Prerpints.org logo
Preprint
Article

Maternal and Infant Histo-Blood Group Antigens (Hbga) Profiles and It’s Influence on Oral Rotavirus Vaccine (Rotarix®) Immunogenicity Among Infants in Zambia

Altmetrics

Downloads

137

Views

65

Comments

0

A peer-reviewed article of this preprint also exists.

Submitted:

30 May 2023

Posted:

31 May 2023

You are already at the latest version

Alerts
Abstract
Live-attenuated, oral rotavirus vaccines have significantly reduced rotavirus-associated diarrhoea morbidity and infant mortality. However, vaccine immunogenicity is diminished in low-income countries. We investigated whether maternal and infant intrinsic susceptibility to rotavirus infection via histo-blood group antigen (HBGA) profiles influenced rotavirus (ROTARIX®) vaccine-induced responses in Zambia. We studied 135 mother-infant pairs under a rotavirus vaccine clinical trial aged 6 to 12 weeks at pre-vaccination up to 12 months old. We determined maternal and infant ABO/H, Lewis, and secretor HBGA phenotypes, and infant FUT2 HBGA genotypes. Vaccine immunogenicity was measured as anti-rotavirus IgA antibody titres. Overall, 34 (31.3%) of children were seroconverted at 14 weeks, and no statistically significant difference in seroconversion was observed across the various HBGA profiles in early infant life. We also observed a statistically significant difference in rotavirus-IgA titres across infant HBGA profiles at 12 months though no statistically significant difference was observed between study arms. There was no association between maternal HBGA profiles and infant vaccine immunogenicity. Overall, infant HBGA was associated with RV-Vaccine immunogenicity at 12 months as opposed to early infant life. Further investigation into the low efficacy of ROTARIX® and appropriate intervention is key to unlocking full vaccine benefits for U5 children.
Keywords: 
Subject: Biology and Life Sciences  -   Immunology and Microbiology

1. Introduction

Rotavirus is known to be the leading cause of moderate to severe acute gastroenteritis in infants and children under the age of 5 years (U5) globally but more so in low- and middle-income countries (LMIC) (1). In 2017 the Global Burden of Disease (GBD) study estimated the total diarrhoea deaths in the U5 population attributable to RV to be between 120,000 and 215,000 (2). Vaccines against rotavirus, such as ROTARIX® (GlaxoSmithKline Biologicals), a G1P[8] strain-derived live attenuated oral vaccine, have been rolled out in national expanded program on immunisation (EPI) schedules of many LMIC, including Zambia in 2013, since recommendation by the World Health Organisation (WHO) (3). Despite successes in reducing rotavirus-associated and all-cause acute gastroenteritis recorded over the years (4), oral vaccine immunogenicity is diminished in LMIC settings where the burden of disease and need for such interventions is greatest in contrast to high-income countries (5,6).
Host-genetic factors may influence Rotavirus vaccine immunogenicity (7–10). Recent studies have shown the role of histo-blood group antigens (HBGA) as cell receptors utilized by rotavirus during infection of the host mucosal epithelium (11). These HBGAs have been shown to mediate rotavirus infection in a P-genotype-specific manner, and this has been shown to have the potential to influence vaccine uptake, and, consequently, efficacy for vaccines based on the G1 P[8] live attenuated strain (12–17). Investigating HBGAs and their potential influence on vaccine immunogenicity provides actionable information that would accelerate efforts to improve vaccine efficacy in U5 children in LMICs.
Histo-blood group antigens include the blood group ABH and Lewis antigen systems, which are encoded by fucosyltransferase-2 (FUT2) and fucosyltransferase-3 (FUT-3) genes, respectively. In addition to red blood cells, these antigens can also be present in other body fluids such as saliva, breastmilk, urine, seminal fluid, and other gastric secretions (18,19). Currently, only a few studies have been conducted in African settings to investigate the role of HBGAs in susceptibility to rotavirus-induced AGE and rotavirus vaccine immunogenicity in children (12,14,16,20), and fewer still on HBGA in breastfeeding mothers (21–23). We aimed to profile the maternal and infant HBGA phenotypes and genotypes and determine their influence on ROTARIX® immunogenicity in a mother-infant pair cohort in Zambia.

2. Materials and Methods

2.1. Study design and participants

This was a prospective cohort study of mother-infant pairs nested under a parent randomised controlled trial (RCT). The parent study aimed to determine the safety and immunogenicity of a third booster dose of ROTARIX® at 9 months of age as published elsewhere (24). Briefly, the study was conducted at a government health facility serving a peri-urban population in Lusaka, Zambia. The parent study enrolled 214 infants aged between 6 and 12 weeks with informed consent obtained from willing mothers who met the full eligibility criteria and agreed to all study procedures throughout the duration of the study. In addition to receiving the routinely administered first and second doses of ROTARIX®, Infants were randomized at baseline at a ratio of 1:1 to either, the intervention arm receiving a booster dose of ROTARIX® concomitantly with measles/rubella (MR) vaccination or the control arm receiving only MR vaccination at 9 months old.
For this study, we randomly selected 135 participants from the parent study using a simple random sampling technique in Stata 17 (StataCorp, College Station, USA). We determined the HBGA phenotype profiles of these selected participants and evaluated ROTARIX® immunogenicity by analyzing rotavirus-specific IgA antibody responses at various time points. Further, a random sample of 90 was selected for FUT2 blood buffy-coat genotyping from the 135 samples using the same method used for phenotype selection.

2.2. Laboratory testing

Determination of the infant ABO and Lewis HBGA phenotypes in saliva
Blood groups A, B, O, H, Lewis a and b HBGA and Lectin (Ulex europaeus agglutinin-1) were detected in saliva using enzyme-linked immunosorbent assay (ELISA) adapted from previously described methods (16,25). Briefly, samples diluted in buffer were incubated at 37°C, followed by incubation at 4°C overnight. The following day, the plate was blocked and later incubated with appropriate antibodies at 37°C. Next, the plate was incubated with an enzyme-conjugated detection antibody, and the reaction was developed using a chromogenic substrate. The reaction was stopped using sulphuric acid while absorbance was read at 450nm on an ELISA plate reader. Similarly, the ELISA method described for saliva above was used to detect Lewis and secretor phenotypes in breast milk with the inclusion of a centrifugation step to remove excess fat before testing.
Determination of the infant FUT2 and FUT3 genotypes
Infant FUT2 genotypes were determined by polymerase chain reaction (PCR) amplification of deoxyribonucleic acid (DNA) extracted from infant buffy coat (QIA Amp® DNA mini kit, Qiagen) based on described methods (16,26,27). Briefly, using extracted genomic DNA and previously published primers, conventional PCR was used to amplify the FUT2 gene and amplicons were confirmed by electrophoresis of PCR products on 1.5% agarose gel. Bands were visualized under ultra-violet (UV) light alongside a molecular marker. Purified DNA amplicons were then used to perform restriction fragment length polymorphism (RFLP) PCR with AvaII enzyme. Restriction fragment length polymorphism (RFLP) PCR reaction was carried out with AvaII (Thermo Scientific®), and products of restriction enzyme digestion were electrophoresed and visualised under UV light. FUT2 genotypes were determined based on RFLP patterns (S 1).
Measurement of Rotavirus specific IgA
A validated sandwich ELISA assay was used to measure rotavirus-specific immunoglobulin A (RV-IgA) in infant plasma samples as described previously (24). The assay employs the use of mock-infected African green monkey kidney (MA104) cells and rotavirus WC3 strain viral lysates. Standard serum with assigned RV-IgA U/mL obtained from the Laboratory for Specialized Clinical Studies, Cincinnati Children’s Hospital Medical Centre (CCHMC), Cincinnati, Ohio, USA, was used to generate and validate an in-house plasma assay standard pooled from ROTARIX®-vaccinated adult donor volunteers. Absorbance was read at 492nm using Gen5 software-enabled EPOCHTM 2 microplate reader (Agilent), and outputs were read as rotavirus-specific IgA titres in U/ml.

2.3. Statistical analysis

To assess the relationship between maternal and infant HBGA profiles and Rotarix® immunogenicity with a 95% confidence level, a sample size of 135 participants was required. Based on a previously reported seroconversion rate of 60.2% (10), a confidence interval of 95%, and a precision of 5% (adjusting for the finite population in the main RCT), a sample size of 135 was obtained using the Cochrane formula. We used simple random sampling to assign random numbers to our sorted IDs in the sampling frame (study participant ID’s from the parent study) after we ’set seed’ for replication purposes. The random numbers were then sorted in ascending order based on the assigned random number. We then picked the first 135 ordered numbers to obtain our sample size.
Participants’ socio-demographic characteristics were summarized as proportions and means (standard deviation) / median (interquartile range) depending on the distribution of the data. Chi-squared or fisher’s exact test were used to determine the association between categorical variables and seroconversion. T-test and analysis of variance (ANOVA) were used to compare geometric mean RV-IgA titres, at each time point, between groups and among groups, respectively. To estimate the geometric mean ratio (GMR) and accompanying confidence intervals, simple linear regression was performed on log-transformed (on the natural log scale) RV-IgA titres. Seroconversion was defined as a four-fold increase or greater in serum RV-IgA titre between pre-vaccination and one-month post-dose -2 ROTARIX® vaccination (24). We assessed the crude effect of child’s baseline characteristics on seroconversion using logistic regression. Statistical significance was set at p-value <0.05. All statistical analyses were performed using Stata version 17 (Stata Corp, College Station, USA).

3. Results

3.1. Participant and Sampling flow chart

For this study, 135/212 (64%) enrolled infants were followed up for the phenotyping analysis, and 90/135 were randomly selected for FUT2 genotyping to determine the secretor genotype. Participants who had no corresponding rotavirus-IgA data at visit 3-, 9-, and 12-months’ time points due to study dropouts were not included in the final analysis as shown in the flow chart (Figure 1).

3.2. Study population characteristics and overall seroconversion frequency

The Median age of infants was 6 weeks (IQR 6-6), with a higher proportion of males 53.9% (n= 69) than females 46.1% (n=59) (Table 1). A total of 71 (55.5%) participants were randomized to the intervention arm, while the rest were in the control arm of the main study. One-hundred twenty-two (95.3%) infants were exclusively breastfed and 39 (30.5%) were HIV-unexposed. Among the children, 21(16.4%) of children were stunted, 9 (7.0%) children were wasted and 2 (1.6%) were malnourished at enrollment. Most infants came from households with shared toilet facilities (81.3%, n=104) and utilised a public tap, pipe water or borehole (3.9 %, n=78), while most mothers had attained secondary level of education (63.3%, n=81). Only 29% of infants enrolled in the study seroconverted, and seroconversion was not statistically associated with any of the infant and mothers’ baseline characteristics (Table 1).

3.3. Mother and infant HBGA profiles

The frequency of maternal Lewis-positive phenotype was 83 (64.8%) while Lewis null phenotype was 45 (35.2%). Secretors and non-secretors were 22(17.2%) and 106(82.8%), respectively (Figure 2a). Among the infant’s ABO phenotypes, group O had 103 (80.5%), followed by group A 22 (17.2%). The frequency of Lewis positive phenotype (Le+) was 64.1%(n=82) while Lewis null (Le-) phenotype was 35.9%(n=46). Similarly, there was a higher frequency of secretors (Se) (81.3%, n=104) compared to non-secretors (se) (18.8%, n=24). In the subset of infants (n=90) on which FUT2 genotypes were determined, the combined secretor genotype was 78% and 22% for non-secretors, while the frequency of homozygous secretor (GG) was 73%, and the heterozygous genotype (GA) was at 4.9% (Figure 2b).

3.3. Maternal and Infant HBGA and RV-IgA Immunogenicity

We plotted trends of infant RV-IgA titres of infant from pre-vaccination to 3-months post-third dose of ROTARIX® for ABO and Lewis phenotypes. There was no observable significant difference in mean RV-IgA titres across ABO phenotype at baseline, post dose-2 and pre-dose 3 time (Figure 3a). However, a significant difference in mean titres was observed for the ABO phenotype at post-dose 3.We also observed a significant difference in mean titres at post-dose 3 for the Lewis phenotypes and Secretor phenotype (Figure not shown).
Using One-way ANOVA, we tested for associations of infant and maternal HBGAs to RV-IgA titre 1-month post-second dose of ROTARIX®, which was our seroconversion determination time-point. We found that infant ABO, Lewis and secretor status were not associated with geometric mean titres (GMTs) at 1-month post second dose (p=0.874, p=0.332 and p=0.279), respectively. Both maternal Lewis and secretor phenotype were not associated with GMTs (p=0.358 and p=0.850). Similarly, no statistically significant difference was observed in geometric mean titre ratio (GMR) for all maternal and infant HBGA profiles (p≥0.05) (Table 2). We further used Chi-square tests to determine whether the seroconversion frequency varied across HBGA phenotypes and we found that there was no statistically significant difference in seroconversion observed across infant ABO phenotype (p=0.929); Lewis phenotype (p=0.775) and Secretor phenotype (p=0.24) and secretor genotype (p=0.289) and we could not we could not adjust for background characteristics since no variables showed significantly lower/higher crude odds of seroconversion (Table 2).

3.3. Maternal and Infant HBGA and RV-IgA Immunogenicity 3-months post dose-3

We performed a one-way ANOVA analysis to determine the effect of HBGAs on rotavirus-IgA geometric mean titres (GMT) at 12 months of infant age,3 months post the third dose of ROTARIX® for those in the intervention arm (Table 3). As our seroconversion definition could not be used at the 12-months time-point, we used simple linear regression to compute the GMT ratios. We observed a significant association between ABO phenotype and GMTs (p=0.02) with lower GMTs observed in group O 3.7 [(95% CI, (.35, 4.08)], compared to group AB 5.28 [(95% CI, 1.86, 15)], group A 5.02 [95% CI, (4.14, 6.07)] while group O had 3.7 [95% CI, (3.35, 4.08)] (Table 4). Infant Lewis positive phenotype Le+ (Le a+b-, Le a-b+, or Le a+b+) had significantly higher GMTs 4.17 [95%CI,3.75, 4.64)] vs 3.57 [(95% CI, (3.03, 4.22)] for Lewis null (Le a-b-); (p=0.015). We also observed significantly higher GMTs in the infant secretor phenotye compared to non-secretors 4.14 [95%CI, (3.78, 4.54)] vs 2.89 [95% CI, (2.26, 3.71)]; p<0.001. Infant secretor genotype, maternal Lewis phenotype, maternal secretor phenotype and treatment arm were not significantly associated to GMTs (p=0.521, p=0.368 and p=0.26) respectively. The ABO phenotypes showed no significant differences in GMT ratio for group AB (p=0.560) and group A (p=0.14) respectively.followed by group A 5.02[95% CI, (4.14, 6.07)] and the least being group O 3.7[96% CI, (3.35, 4.08)]; p=0.002. Similarly among the Lewis phenotype, Lewis positive phenotype Le+ (Le a+b-, Le a-b+, or Le a+b+) showed significantly higher GMTs 4.17 [95% CI, (3.75, 4.63)} compared to the null phenotype 3.57 [95% CI, (3.03, 4.22)]; p=0.002.. Furthermore, at phenotype level, secretors showed a statistically higher GMT ratio compared to non-secretors (p< 0.001), though genotype (FUT2) genotype was not found to be statistically significant(p=0.063). Maternal Lewis phenotype and maternal secretor phenotype were not significant for both adjusted and undjusted GMT ratio (p=0.688, p=0.12) respectively (Table 3).
A third booster dose of ROTARIX® at 9 months showed no significant effect on immunogenicity between control and intervention arms at 12 months for both GMTs and GMT ratio (p=0.26 and p=0.479) respectively All other HBGA variables were not significantly associated with GMT ratio (Table 3).

4. Discussion

To the best of our knowledge, this is the first study conducted in Zambia that has attempted to assess both genotypic and phenotypic secretor effects on Rotarix® immunogenicity in U5 children and accounting for the influence of maternal profiles. Our study investigating the influence of maternal and infant histo-blood group antigens on Rotarix® immunogenicity yielded three main findings: (i) There was no association between maternal and infant HBGAs on vaccine immunogenicity at 1 month post-second dose; (ii) Maternal HBGAs were of no effect on vaccine immunogenicity at 12-months of infant age and (iii) infant HBGAs are associated with immunogenicity much later in life at 12-months of age. These findings both correlate and contradict various publications on this subject.
Several studies have shown that HBGAs are important in host-pathogen interactions and their potential role in infection and vaccine uptake has been hypothesized (17,22,23,28–32). Our findings that HBGA was not significantly associated with vaccine immunogenicity in early infant life were very similar to those from a study in neighboring Malawi, which found no association between ABO, Lewis and secretor status with seroconversion or vaccine shedding early post-vaccination (33). The same study showed high concordance of secretor genotype and phenotype proportions though neither profile was found to influence immunogenicity post-vaccination, as in our study (33). Contrary to these findings, a study conducted in Nicaragua showed that ABO blood groups seem to be significantly associated with rotavirus vaccine immunogenicity (14), as was shown in our study at 12 months of infant age with significantly varied GMTs, GMRs and GMFR reported across ABO and secretor phenotypes (14). These data support the hypothesis that HBGAs impact vaccine uptake in children and consequently impact immunogenicity, similar to studies conducted elsewhere (15,34,35). We postulate that the observed difference in immunogenicity between sub-Saharan Africa and North American countries might be due to the inherent genetic polymorphisms which dictate the different phenotypic profiles characteristic of these unique populations. Evolutionary, selective pressure acting on pathogens might also influence susceptibility through host-range specificity, which may influence vaccine immune responses depending on the prevalence of phenotypes in a particular population.
Of note, our study showed a higher rate of seroconversion among secretors compared to non-secretors, as previously documented (35–37). This is not surprising as literature has shown that secretors express HBGAs on their gut-mucosal epithelia, which serve as receptors for rotavirus attachment; -in this case, a vaccine-derived live attenuated virus, which could explain the higher immune responses seen in secretors compared to non-secretors. We also showed consistency between secretor genotype and phenotype and immunogenicity at 12 months which further affirms our findings and strengthens our confidence in the observed outcomes.
In addition to secretor status, the Lewis phenotype has also been shown to impact vaccine efficacy as reported elsewhere (35,38). Other studies have further associated secretor and Lewis phenotypes with RV-diarrhoea through other mechanisms such as the modulation of the gut microbiota (22) while other researchers hypothesize an influence on infant gut microbiota which influences vaccine immunogenicity (39,40).
While we may not fully understand the role malnutrition plays in vaccine immunogenicity, it has been hypothesized that lack of essential micronutrients (e.g. Iron, Zinc and vitamin A) impairs IgA antibody production, specific T-cell mediated production and gut barrier function (23,30). We, therefore, think this is a possible explanation for the observed effect on ROTARIX® immunogenicity in our study.
While our study only focused on the association, other studies investigated the interaction between HBGAs and rotaviruses at a molecular level which has been shown to occur in a genotype-specific fashion. Using Nuclear Magnetic Resonance techniques (NMR), one study found that A-type antigens are recognized as receptors for human rotaviruses while the human P[8] rotavirus Wa strain did not recognize A-type HBGAs (41), while another similar study showed that rotavirus genogroups P[4] P[6] and P[8] of the VP8* subunits recognized Lewis-b and/ H-type-1 antigens and therefore important factors to be considered in the production of P-type based vaccines (34). More studies have shown that rotaviruses have host-range specificity based on the prevalence of certain HBGA phenotypes. This varies from region to region, thereby influencing both strain diversity and host-susceptibility which is an important evolutionary attribute (17,28,32,42–44). Studies conducted to assess host-genetic susceptibility via HBGA and vaccine immunogenicity strongly suggest that this relationship could partly explain why vaccine efficacy is poor in LMICs compared to high-income countries (HIC) (42–44).
We find the contrasting immunogenicity pictures at 1-month post second dose and 12 months in our study a very interesting phenomenon worthy of more attention. We agree with the theory that there is more influence of maternal factors such as maternal immunity and non-immunogenic components of breast milk interfering with the infants’ immune responses, as shown by previous studies conducted in-country (9,10). Importantly, we observed from our trend plots that at 9 months, RV-IgA titres were significantly higher than all the earlier time-points even before the intervention arm received the third booster dose of Rotarix®. Therefore, the significant increases seen in titres at 12 months were most likely due to natural exposure to wild-type rotavirus seeing that there was no statistically significant difference observed in titres between intervention and control arms of the study. It is therefore plausible that the group AB and A receptors may have been interacting with wild type rotavirus through the VP8 subunit in a “type-specific manner” as documented elsewhere (42).
Though no association was between maternal HBGAs, and infant RV-IgA titres was observed in our results, we find it plausible that mother’s secreted HBGAs in breast milk could be serving as decoy-receptors and thereby limiting the available fraction of vaccine material to be actively taken up by the infants, thereby resulting in the lack of seroconvertors and insignificant GMR observed 1-month post second dose. This phenomenon also feeds into another hypothesized theory of a developmental delay in the biosynthesis of HBGAs, stating that in early infant life, HBGAs are not fully expressed in gut-mucosal epithelial tissue and, therefore, fewer attachment sites for the vaccine-derived virus leading to sub-optimal uptake. However, as the child grows and expresses more HBGAs in their body tissue and is gradually weaned off breast milk, RV-IgA titres seem to show an increase, as seen at 12 months in our study cohort. It is, however, unclear whether this increase in titres is due to a delayed effect of vaccination or attributable to wild-type infections. However, HBGAs could likely be playing a part in the titer kinetics.
Though our study showed no effect of maternal HBGAs on vaccine immunogenicity, a study elsewhere reported a higher seroconversion frequency in children born to non-secretor mothers compared to secretor-positive mothers (48). Interestingly, this study, like ours, found that infant Lewis and secretor phenotype were not associated with seroconversion at 18 weeks (48). The working hypothesis is that children born to non-secretor mothers have a reduced risk of interference compared to those born to secretor-positive mothers who shed decoy receptors in breast milk.
We also note that the Lewis-null phenotype Lewis (non-secretor) had very low immunogenicity measures even at 12 months of infant age. This might be due to the host-range specificity that has been shown regarding rotavirus in literature. It is well documented that most P[4], P[6] and P[8] human rotaviruses recognize H-type 1 and Lewis-B antigens (17,42,49,50) and therefore plausible that the Lewis null (non-secretors) had no receptors for the vaccine-derived G1P[8] strain, leading to the low vaccine-response observed.
The strengths of our study were that our study population was drawn from a randomized controlled trial and hence reduced the risk of bias as well as accorded the statistical power to control for confounding variables. Employing both phenotypic and genotypic methods for infant secretor genotyping also strengthened our interpretation of results for our outcome variable. Our study, however, also had several limitations. Firstly, our sample size was small hence the wide confidence intervals which could also have been influenced by wide variation within our study population. A larger cohort study and a longer follow-up period would be ideal to measure the effect size of our outcome variable accurately. We did not assess the confounding effect of maternal antibodies on immunogenicity in this study. The use of more phenotypic than molecular techniques, which are more robust, also reduced the sensitivity of our assays. It would also be important to conduct this study in children presenting with diarrhoea where aetiology and vaccine shedding can be assessed in addition to serological work.

5. Conclusions

In summary, this study found that HBGAs are associated with ROTARIX® immunogenicity. We recommend that future research be focused on understanding the full extent of this influence, which will inform the design of more efficacious vaccines that will bypass this gut-mucosal barrier and improve efficacy in LMICs. Such studies will help inform policy on strategies aimed at improving vaccination outcomes in U5 children and consequently improve their health status.
It would also be very critical to set up surveillance systems that will monitor the molecular epidemiology of wild-type rotaviruses since the introduction of ROTARIX® to monitor the evolutionary patterns occurring in nature. This will enable the idealization of appropriate interventions and enable us to move toward a more proactive approach targeted at eliminating rotavirus soon.

Author Contributions

Conceptualization R.C., S.B., S.M. and M.S.; methodology, S.M., B.P., M.C., N.L., O.C., C.C. and M.S.; formal analysis, B.P and M.C; Investigation- A.C., N.L., M.C.C., N.S., C.C., R.V., K.N., C.M., and I.M.; writing—original draft preparation, A.C.; writing—review and editing, R.C., S.B., N.L., M.C.C., C.M.,O.C., I.M., M.C., and B.P; visualization, B.P and M.C.; funding acquisition R.C.; All authors have read and agreed to the published version of the manuscript.

Funding

This study is part of the EDCTP2 Programme supported by the European Union (grant number TMA2016SF-1511-ROVAS-2). This study was also supported by the Bill and Melinda Gates Foundation (grant No. OPP1162810 BMGF:00631000362).

Institutional Review Board Statement

The parent clinical trial was approved by UNZABREC (Ref 002-03-18) and registered with the Pan African Clinical Trial Registry (Ref: PACTR201804003096919). This nested study was also approved by the University of Zambia Biomedical Ethics Committee (Ref: 622-2019).

Informed Consent Statement

Informed consent was obtained from all participants under the parent clinical trial. Participant informed consent for the nested study to test samples was waived as all procedures and tests conducted on participant samples had already been consented to in the parent clinical trial. No contact was made with participants and no unconsented tests were carried out on samples used for the accomplishment of this work.

Data Availability Statement

The data presented in this study are available on request from the corresponding author. The data are not publicly available due to policy restrictions on institutional data publication.

Acknowledgments

We thank the infants and their mothers for their participation in the parent clinical trial which provided samples for this study. We extend our gratitude to the study Research Nurses Yvonne Kumwimba, Fridah Madyabi, Margaret Chisambi, Chilombo, the Data Associate Emmanuel Mwape and the Research Assistant Seversky Buyaala. We also thank Cynthia Phiri Mubanga and Sekayi Tigere for the technical lab support and all other CIDRZ Enteric Diseases and Vaccines Research Unit staff who contributed to this work.

Conflicts of Interest

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

References

  1. Lanata, C.F.; Fischer-Walker, C.L.; Olascoaga, A.C.; Torres, C.X.; Aryee, M.J.; Black, R.E. ; for the Child Health Epidemiology Reference Group of the World Health Organization and UNICEF Global Causes of Diarrheal Disease Mortality in Children <5 Years of Age: A Systematic Review. PLOS ONE 2013, 8, e72788. [Google Scholar] [CrossRef]
  2. Abbafati C, Abbas KM, Abbasi-Kangevari M, Abd-Allah F, Abdelalim A, Abdollahi M, et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 2020, 396, 1204–1222. [CrossRef]
  3. Chilengi, R.; Rudd, C.; Bolton, C.; Guffey, B.; Masumbu, P.K.; Stringer, J. Successes, Challenges and Lessons Learned in Accelerating Introduction of Rotavirus Immunisation in Zambia. World J. Vaccines 2015, 05, 43–53. [Google Scholar] [CrossRef]
  4. Burnett, E.; Jonesteller, C.L.; Tate, J.E.; Yen, C.; Parashar, U.D. Global Impact of Rotavirus Vaccination on Childhood Hospitalizations and Mortality From Diarrhea. J. Infect. Dis. 2017, 215, 1666–1672. [Google Scholar] [CrossRef] [PubMed]
  5. James A Church, Edward P Parker, Beth Kirkpatrick4, Nicholas C Grassly AJ, Prendergast. Interventions to Improve Oral Vaccine Performance in developing countries : A Systematic Review and Meta-analysis Protocol Information. 2017;(December):1–41.
  6. Kazimbaya, K.M.; Bosomprah, S.; Simuyandi, M.; Chisenga, C.C.; Chilengi, R.; Munsaka, S. Efficacy and Effectiveness of Rotavirus Vaccine on Incidence of Diarrhoea among Children: A Meta-analysis. Pediatr. Infect. Dis. Open Access 2018, 03. [Google Scholar] [CrossRef]
  7. Velasquez DE, Parashar U, Jiang B. Decreased performance of live attenuated, oral rotavirus vaccines in low-income settings : causes and contributing factors. Expert Rev Vaccines. 2018;00(00):1–17.
  8. Mwape, I.; Bosomprah, S.; Mwaba, J.; Mwila-Kazimbaya, K.; Laban, N.M.; Chisenga, C.C.; Sijumbila, G.; Simuyandi, M.; Chilengi, R. Immunogenicity of rotavirus vaccine (RotarixTM) in infants with environmental enteric dysfunction. PLOS ONE 2017, 12, e0187761. [Google Scholar] [CrossRef] [PubMed]
  9. Mwila-Kazimbaya, K.; Garcia, M.P.; Bosomprah, S.; Laban, N.M.; Chisenga, C.C.; Permar, S.R.; Simuyandi, M.; Munsaka, S.; Chilengi, R. Effect of innate antiviral glycoproteins in breast milk on seroconversion to rotavirus vaccine (Rotarix) in children in Lusaka, Zambia. PLOS ONE 2017, 12, e0189351. [Google Scholar] [CrossRef]
  10. Chilengi, R.; Simuyandi, M.; Beach, L.; Mwila, K.; Becker-Dreps, S.; Emperador, D.M.; Velasquez, D.E.; Bosomprah, S.; Jiang, B. Association of Maternal Immunity with Rotavirus Vaccine Immunogenicity in Zambian Infants. PLOS ONE 2016, 11, e0150100. [Google Scholar] [CrossRef]
  11. Xu S, Liu Y, Tan M, Zhong W, Zhao D, Jiang X, et al. Molecular basis of P [ 6 ] and P [ 8 ] major human rotavirus VP8 * domain interactions with histo-blood group antigens. 2019.
  12. E Armah, G.; Cortese, M.M.; E Dennis, F.; Yu, Y.; Morrow, A.L.; McNeal, M.M.; Lewis, K.D.C.; A Awuni, D.; Armachie, J.; Parashar, U.D. Rotavirus Vaccine Take in Infants Is Associated With Secretor Status. J. Infect. Dis. 2018, 219, 746–749. [Google Scholar] [CrossRef]
  13. Pollock L, Bennett A, Jere KC, Dube Q, Mandolo J, Bar-Zeev N, et al. Non-secretor histo-blood group antigen phenotype is associated with reduced risk of clinical rotavirus vaccine failure in Malawian infants. Clin Infect Dis. 2018;(Xx):1–7.
  14. Bucardo, F.; Nordgren, J.; Reyes, Y.; Gonzalez, F.; Sharma, S.; Svensson, L. The Lewis A phenotype is a restriction factor for Rotateq and Rotarix vaccine-take in Nicaraguan children. Sci. Rep. 2018, 8, 1–8. [Google Scholar] [CrossRef]
  15. Lee, B.; Dickson, D.M.; Decamp, A.C.; Colgate, E.R.; A Diehl, S.; Uddin, M.I.; Sharmin, S.; Islam, S.; Bhuiyan, T.R.; Alam, M.; et al. Histo–Blood Group Antigen Phenotype Determines Susceptibility to Genotype-Specific Rotavirus Infections and Impacts Measures of Rotavirus Vaccine Efficacy. J. Infect. Dis. 2018, 217, 1399–1407. [Google Scholar] [CrossRef] [PubMed]
  16. Nordgren, J.; Sharma, S.; Bucardo, F.; Nasir, W.; Günaydın, G.; Ouermi, D.; Nitiema, L.W.; Becker-Dreps, S.; Simpore, J.; Hammarström, L.; et al. Both Lewis and Secretor Status Mediate Susceptibility to Rotavirus Infections in a Rotavirus Genotype–Dependent Manner. Clin. Infect. Dis. 2014, 59, 1567–1573. [Google Scholar] [CrossRef] [PubMed]
  17. Liu, Y.; Huang, P.; Tan, M.; Liu, Y.; Biesiada, J.; Meller, J.; Castello, A.A.; Jiang, B.; Jiang, X. Rotavirus VP8*: Phylogeny, Host Range, and Interaction with Histo-Blood Group Antigens. J. Virol. 2012, 86, 9899–9910. [Google Scholar] [CrossRef] [PubMed]
  18. Abegaz, S.B. Human ABO Blood Groups and Their Associations with Different Diseases. BioMed Res. Int. 2021, 2021, 1–9. [Google Scholar] [CrossRef] [PubMed]
  19. Daniels, G. Human Blood groups, Second Edition. 2016. 1–23 p.
  20. Jiang X, Huang P, Zhong W, Tan M, Farkas T, Morrow AL, et al. Human Milk Contains Elements That Block Binding of Noroviruses to Human Histo – Blood Group Antigens in Saliva. 2004;3039.
  21. Williams, F.B.; Kader, A.; Colgate, E.R.; Dickson, D.M.; Carmolli, M.; Uddin, M.I.; Sharmin, S.; Islam, S.; Bhuiyan, T.R.; Alam, M.; et al. Maternal Secretor Status Affects Oral Rotavirus Vaccine Response in Breastfed Infants in Bangladesh. J. Infect. Dis. 2020, 224, 1147–1151. [Google Scholar] [CrossRef]
  22. Colston, J.M.; Francois, R.; Pisanic, N.; Yori, P.P.; McCormick, B.J.J.; Olortegui, M.P.; Gazi, A.; Svensen, E.; Ahmed, M.M.M.; Mduma, E.; et al. Effects of Child and Maternal Histo-Blood Group Antigen Status on Symptomatic and Asymptomatic Enteric Infections in Early Childhood. J. Infect. Dis. 2019, 220, 151–162. [Google Scholar] [CrossRef]
  23. Parker, E.P.; Ramani, S.; A Lopman, B.; A Church, J.; Iturriza-Gómara, M.; Prendergast, A.J.; Grassly, N.C.; Colvin, E.; Kosek, M.N.; Kang, G.; et al. Causes of impaired oral vaccine efficacy in developing countries. Futur. Microbiol. 2018, 13, 97–118. [Google Scholar] [CrossRef]
  24. Laban, N.M.; Bosomprah, S.; Simuyandi, M.; Chibuye, M.; Chauwa, A.; Chirwa-Chobe, M.; Sukwa, N.; Chipeta, C.; Velu, R.; Njekwa, K.; et al. Evaluation of ROTARIX® Booster Dose Vaccination at 9 Months for Safety and Enhanced Anti-Rotavirus Immunity in Zambian Children: A Randomised Controlled Trial. Vaccines 2023, 11, 346. [Google Scholar] [CrossRef]
  25. E Armah, G.; O Sow, S.; Breiman, R.F.; Dallas, M.J.; Tapia, M.D.; Feikin, D.R.; Binka, F.N.; Steele, A.D.; Laserson, K.F.; A Ansah, N.; et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. Lancet 2010, 376, 606–614. [Google Scholar] [CrossRef]
  26. Elmgren ASDS and S for PM in the HL( F) GEMG of the HLBGS, Larson G. DNA Sequencing and Screening for Point Mutations in the Human Lewis ( FUT3 ) Gene Enables Molecular Genotyping of the Human Lewis Blood Group Sytem. 1996;97–103.
  27. Silva, L.M.; Carvalho, A.S.; Guillon, P.; Seixas, S.; Azevedo, M.; Almeida, R.; Ruvoën-Clouet, N.; Reis, C.A.; Le Pendu, J.; Rocha, J.; et al. Infection-associated FUT2 (Fucosyltransferase 2) genetic variation and impact on functionality assessed by in vivo studies. Glycoconj. J. 2009, 27, 61–68. [Google Scholar] [CrossRef]
  28. Sun, X.; Guo, N.; Li, J.; Yan, X.; He, Z.; Li, D.; Jin, M.; Xie, G.; Pang, L.; Zhang, Q.; et al. Rotavirus infection and histo-blood group antigens in the children hospitalized with diarrhoea in China. Clin. Microbiol. Infect. 2016, 22, 740–e1. [Google Scholar] [CrossRef]
  29. de Mattos, L.C. Structural diversity and biological importance of ABO, H, Lewis and secretor histo-blood group carbohydrates. Rev. Bras. de Hematol. e Hemoter. 2016, 38, 331–340. [Google Scholar] [CrossRef] [PubMed]
  30. Velasquez, D.E.; Parashar, U.; Jiang, B. Decreased performance of live attenuated, oral rotavirus vaccines in low-income settings: causes and contributing factors. Expert Rev. Vaccines 2017, 17, 1–17. [Google Scholar] [CrossRef]
  31. Payne, D.C.; Currier, R.L.; Staat, M.A.; Sahni, L.C.; Selvarangan, R.; Halasa, N.B.; Englund, J.A.; Weinberg, G.A.; Boom, J.A.; Szilagyi, P.G.; et al. Epidemiologic Association Between FUT2 Secretor Status and Severe Rotavirus Gastroenteritis in Children in the United States. JAMA Pediatrics 2015, 169, 1040–1045. [Google Scholar] [CrossRef]
  32. Heggelund, J.E.; Varrot, A.; Imberty, A.; Krengel, U. Histo-blood group antigens as mediators of infections. Curr. Opin. Struct. Biol. 2017, 44, 190–200. [Google Scholar] [CrossRef] [PubMed]
  33. Pollock, L.; Bennett, A.; Jere, K.C.; Dube, Q.; Mandolo, J.; Bar-Zeev, N.; Heyderman, R.S.; A Cunliffe, N.; Iturriza-Gomara, M. Nonsecretor Histo–blood Group Antigen Phenotype Is Associated With Reduced Risk of Clinical Rotavirus Vaccine Failure in Malawian Infants. Clin. Infect. Dis. 2018, 69, 1313–1319. [Google Scholar] [CrossRef] [PubMed]
  34. Jiang, X.; Liu, Y.; Tan, M. Histo-blood group antigens as receptors for rotavirus, new understanding on rotavirus epidemiology and vaccine strategy. Emerg. Microbes Infect. 2017, 6, e22. [Google Scholar] [CrossRef]
  35. Kazi, A.M.; Cortese, M.M.; Yu, Y.; Lopman, B.; Morrow, A.L.; Fleming, J.A.; McNeal, M.M.; Steele, A.D.; Parashar, U.D.; Zaidi, A.K.M.; et al. Secretor and Salivary ABO Blood Group Antigen Status Predict Rotavirus Vaccine Take in Infants. J. Infect. Dis. 2017, 215, 786–789. [Google Scholar] [CrossRef]
  36. E Armah, G.; Cortese, M.M.; E Dennis, F.; Yu, Y.; Morrow, A.L.; McNeal, M.M.; Lewis, K.D.C.; A Awuni, D.; Armachie, J.; Parashar, U.D. Rotavirus Vaccine Take in Infants Is Associated With Secretor Status. J. Infect. Dis. 2018, 219, 746–749. [Google Scholar] [CrossRef]
  37. Lee, B.; Dickson, D.M.; Decamp, A.C.; Colgate, E.R.; A Diehl, S.; Uddin, M.I.; Sharmin, S.; Islam, S.; Bhuiyan, T.R.; Alam, M.; et al. Histo–Blood Group Antigen Phenotype Determines Susceptibility to Genotype-Specific Rotavirus Infections and Impacts Measures of Rotavirus Vaccine Efficacy. J. Infect. Dis. 2018, 217, 1399–1407. [Google Scholar] [CrossRef]
  38. Yang, T.-A.; Hou, J.-Y.; Huang, Y.-C.; Chen, C.-J. Genetic Susceptibility to Rotavirus Gastroenteritis and Vaccine Effectiveness in Taiwanese Children. Sci. Rep. 2017, 7, 6412–6412. [Google Scholar] [CrossRef]
  39. Harris, V.; Ali, A.; Fuentes, S.; Korpela, K.; Kazi, M.; Tate, J.; Parashar, U.; Wiersinga, W.J.; Giaquinto, C.; de Weerth, C.; et al. Rotavirus vaccine response correlates with the infant gut microbiota composition in Pakistan. Gut Microbes 2017, 9, 93–101. [Google Scholar] [CrossRef] [PubMed]
  40. Sharma, S.; Nordgren, J. Effect of Infant and Maternal Secretor Status on Rotavirus Vaccine Take—An Overview. Viruses 2021, 13, 1144. [Google Scholar] [CrossRef]
  41. Böhm, R.; Fleming, F.E.; Maggioni, A.; Dang, V.T.; Holloway, G.; Coulson, B.S.; von Itzstein, M.; Haselhorst, T. Revisiting the role of histo-blood group antigens in rotavirus host-cell invasion. Nat. Commun. 2015, 6, 5907–5907. [Google Scholar] [CrossRef] [PubMed]
  42. Huang, P.; Xia, M.; Tan, M.; Zhong, W.; Wei, C.; Wang, L.; Morrow, A.; Jiang, X. Spike Protein VP8* of Human Rotavirus Recognizes Histo-Blood Group Antigens in a Type-Specific Manner. J. Virol. 2012, 86, 4833–4843. [Google Scholar] [CrossRef] [PubMed]
  43. Cooling, L. Blood Groups in Infection and Host Susceptibility. Clin. Microbiol. Rev. 2015, 28, 801–870. [Google Scholar] [CrossRef] [PubMed]
  44. Van Trang N, Vu HT, Le NT, Huang P, Jiang X, Anh DD. Association between norovirus and rotavirus infection and histo-blood group antigen types in vietnamese children. J Clin Microbiol. 2014, 52, 1366–1374. [CrossRef]
  45. Bekdas M, Demircioglu F, Goksugur SB, Kucukbayrak B. Is there a relationship between rotavirus positive gastroenteritis and ABO blood groups? A retrospective cohort study. Arch Argent Pediatr. 2014, 112, 345–348.
  46. Mihala G, Ware RS, Cheung C, Lambert SB, Sly PD, Whiley DM, et al. Intestinal shedding of enteric agents in histo-blood group antigen-secretor children in an Australian community-based birth cohort study. J Pediatr Neonatal Individ Med. 2022, 11, 1–13.
  47. Ramani, S.; Giri, S. Influence of histo blood group antigen expression on susceptibility to enteric viruses and vaccines. Curr. Opin. Infect. Dis. 2019, 32, 445–452. [Google Scholar] [CrossRef]
  48. Williams, F.B.; Kader, A.; Colgate, E.R.; Dickson, D.M.; Carmolli, M.; Uddin, M.I.; Sharmin, S.; Islam, S.; Bhuiyan, T.R.; Alam, M.; et al. Maternal Secretor Status Affects Oral Rotavirus Vaccine Response in Breastfed Infants in Bangladesh. J. Infect. Dis. 2020, 224, 1147–1151. [Google Scholar] [CrossRef] [PubMed]
  49. Xu S, Liu Y, Tan M, Zhong W, Zhao D, Jiang X, et al. Molecular basis of P[6] and P[8] major human rotavirus VP8* domain interactions with histo-blood group antigens. bioRxiv [Internet]. 2019;512301. [CrossRef]
  50. Ayouni, S.; Sdiri-Loulizi, K.; de Rougemont, A.; Estienney, M.; Ambert-Balay, K.; Aho, S.; Hamami, S.; Aouni, M.; Neji-Guediche, M.; Pothier, P.; et al. Rotavirus P[8] Infections in Persons with Secretor and Nonsecretor Phenotypes, Tunisia. Emerg. Infect. Dis. 2015, 21, 2055–2058. [Google Scholar] [CrossRef] [PubMed]
Preprints 75184 g001
Figure 1. Analysis Flow Chart.
Figure 1. Analysis Flow Chart.
Preprints 75184 g001
Preprints 75184 g002
Figure 2. (a) Maternal HBGA profiles: Secretor Status: secretor (Se) and non-secretor (se); Lewis phenotype: Lewis positive (Le+) and Lewis null (Le-). (b) Infant HBGA profiles; ABH: A, B, AB, and O; Secretor Status: secretor (Se) and non-secretor (se); Lewis phenotype: Lewis positive (Le+) and Lewis null (Le-). Abbreviations: Le-Lewis; Se -secretor; se-non-secretor; FUT2-Fuscosyltransferase-2.
Figure 2. (a) Maternal HBGA profiles: Secretor Status: secretor (Se) and non-secretor (se); Lewis phenotype: Lewis positive (Le+) and Lewis null (Le-). (b) Infant HBGA profiles; ABH: A, B, AB, and O; Secretor Status: secretor (Se) and non-secretor (se); Lewis phenotype: Lewis positive (Le+) and Lewis null (Le-). Abbreviations: Le-Lewis; Se -secretor; se-non-secretor; FUT2-Fuscosyltransferase-2.
Preprints 75184 g002

Seroconverted
Mother-infant pairs (N=128) No。(n = 91, 71.1%) Yes。(n = 37, 28.9%)) P-value
n (% of total) n (%) n (%)
Infant Characteristics
Age (Weeks)
Median (IQR) 6 (6-6) 6 (6-6) 6 (6-6) 0.442
Mean (SD) 6 (0.6) 6 (0.6) 5.9 (0.7)
Sex
Male 69 (53.9) 51 (73.9) 18 (26.0) 0.447
Female 59 (46.1) 40 (67.7) 19 (32.2)
Feeding
Exclusive Breastfeeding 122 (95.3) 86 (70.4) 36 (29.5) 0.672
Mixed Feeding 6 (4.7) 5 (83.3) 1 (16.6)
Birthweight (kg)
< 2.5 5 (3.9) 3 (60.0) 2 (40.0) 0.626
≥ 2.5 123 (96.1) 88 (71.5) 35 (28.4)
HIV Exposure
Not Exposed 89 (69.5) 62 (69.6) 27 (30.3) 0.590
Exposed 39 (30.5) 28 (73.6) 10 (26.3)
Nutritional Status
Stunted
No (HAZ ≥ -2) 107 (83.6) 78 (72.8) 29 (27.1) 0.310
Yes (HAZ < -2) 21 (16.4) 13 (61.9) 8 (38.0)
Wasted
No (WAZ ≥ -2) 119 (93.0) 86 (72.2) 33 (27.7) 0.281
Yes (WAZ < -2) 9 (7.0) 5 (55.5) 4 (44.4)
Mother’s Characteristics
Age (years)
<20 20 (15.6) 15 (75.0) 5 (25.0) 0.080
20-24 45 (35.2) 37 (82.2) 8 (17.7)
25-29 34 (26.6) 19 (55.8) 15 (44.1)
≥30 29 (22.7) 20 (68.9) 9 (31.0)
Highest Education Level
None 6 (4.7) 4 (66.7) 2 (33.3) 0.470*
Primary 40 (31.3) 25 (62.5) 15 (37.5)
Secondary 81 (63.3) 61 (75.3) 20 (24.6)
Tertiary 1 (0.8) 1 (100.0) 0 (0.0)
Water Source
Piped into house/yard 45 (35.2) 33 (75.0) 12 (25.0) 0.882
Protected well 5 (3.9) 4 (80.0) 1 (20.0)
Public borehole/tap and pipe 78 (60.9) 54 (80.0) 24 (20.0)
Shared Toilet Facility
No 24 (18.8) 17 (70.8) 7 (29.1) 0.975
Yes 104 (81.3) 74 (71.1) 30 (28.8)
Type of Toilet Facility
Flushing toilet 26 (20.3) 17 (65.4) 9 (34.6) 0.476
Pit latrine 102 (79.7) 74 (72.6) 28 (27.5)
Abbreviations: IQR- Interquartile range; Std.Dev- standard deviation; Kg- Kilogram; HAZ (height-for-age Z-score); HIV (human immunodeficiency virus); MR (measles-rubella vaccine); RV-IgA (rotavirus specific immunoglobulin A); WAZ (weight-for-age Z-score); WLZ (weight-for-length Z-score). * Fisher’s exact test.
Preprints 75184 g003
Figure 3. (a) Trend plot for infant RV-IgA titre kinetics for ABO phenotype. The green, blue and marron lines represent trends of RV-IgA titres over time for blood groups A, AB, and O respectively. (b) Trend plot for infant RV-IgA titre kinetics for Lewis phenotype. The green and marron lines represent the trends of RV-IgA titres over time for the Lewis-null (Le-) and Lewis-positive (Le+) phenotypes respectively.Figure 3(a) and 3(b). Trends in infant rotavirus specific immunoglobulin A (RV-IgA) titres pre and post rotavirus vaccination compared infant and maternal HBGA profiles. Each circle represents an infant’s log10 RV-IgA titre. Yellow circles with lines represent means and standard errors of log transformed RV-IgA titres. Abbreviations: Le-Lewis.
Figure 3. (a) Trend plot for infant RV-IgA titre kinetics for ABO phenotype. The green, blue and marron lines represent trends of RV-IgA titres over time for blood groups A, AB, and O respectively. (b) Trend plot for infant RV-IgA titre kinetics for Lewis phenotype. The green and marron lines represent the trends of RV-IgA titres over time for the Lewis-null (Le-) and Lewis-positive (Le+) phenotypes respectively.Figure 3(a) and 3(b). Trends in infant rotavirus specific immunoglobulin A (RV-IgA) titres pre and post rotavirus vaccination compared infant and maternal HBGA profiles. Each circle represents an infant’s log10 RV-IgA titre. Yellow circles with lines represent means and standard errors of log transformed RV-IgA titres. Abbreviations: Le-Lewis.
Preprints 75184 g003

Seroconverted
Mother-infant pairs (N=128) No。(n = 91, 71.1%) Yes。(n = 37, 28.9%)) P-value
n (% of total) n (%) n (%)
Infant Characteristics
Age (Weeks)
Median (IQR) 6 (6-6) 6 (6-6) 6 (6-6) 0.442
Mean (SD) 6 (0.6) 6 (0.6) 5.9 (0.7)
Sex
Male 69 (53.9) 51 (73.9) 18 (26.0) 0.447
Female 59 (46.1) 40 (67.7) 19 (32.2)
Feeding
Exclusive Breastfeeding 122 (95.3) 86 (70.4) 36 (29.5) 0.672
Mixed Feeding 6 (4.7) 5 (83.3) 1 (16.6)
Birthweight (kg)
< 2.5 5 (3.9) 3 (60.0) 2 (40.0) 0.626
≥ 2.5 123 (96.1) 88 (71.5) 35 (28.4)
HIV Exposure
Not Exposed 89 (69.5) 62 (69.6) 27 (30.3) 0.590
Exposed 39 (30.5) 28 (73.6) 10 (26.3)
Nutritional Status
Stunted
No (HAZ ≥ -2) 107 (83.6) 78 (72.8) 29 (27.1) 0.310
Yes (HAZ < -2) 21 (16.4) 13 (61.9) 8 (38.0)
Wasted
No (WAZ ≥ -2) 119 (93.0) 86 (72.2) 33 (27.7) 0.281
Yes (WAZ < -2) 9 (7.0) 5 (55.5) 4 (44.4)
Mother’s Characteristics
Age (years)
<20 20 (15.6) 15 (75.0) 5 (25.0) 0.080
20-24 45 (35.2) 37 (82.2) 8 (17.7)
25-29 34 (26.6) 19 (55.8) 15 (44.1)
≥30 29 (22.7) 20 (68.9) 9 (31.0)
Highest Education Level
None 6 (4.7) 4 (66.7) 2 (33.3) 0.470*
Primary 40 (31.3) 25 (62.5) 15 (37.5)
Secondary 81 (63.3) 61 (75.3) 20 (24.6)
Tertiary 1 (0.8) 1 (100.0) 0 (0.0)
Water Source
Piped into house/yard 45 (35.2) 33 (75.0) 12 (25.0) 0.882
Protected well 5 (3.9) 4 (80.0) 1 (20.0)
Public borehole/tap and pipe 78 (60.9) 54 (80.0) 24 (20.0)
Shared Toilet Facility
No 24 (18.8) 17 (70.8) 7 (29.1) 0.975
Yes 104 (81.3) 74 (71.1) 30 (28.8)
Type of Toilet Facility
Flushing toilet 26 (20.3) 17 (65.4) 9 (34.6) 0.476
Pit latrine 102 (79.7) 74 (72.6) 28 (27.5)
Table 1. Mother and infant baseline characteristics and seroconversion status 1-month ROTARIX® dose 2.
Table 1. Mother and infant baseline characteristics and seroconversion status 1-month ROTARIX® dose 2.
Seroconverted
Mother-infant pairs (N=128) No。(n = 91, 71.1%) Yes。(n = 37, 28.9%)) P-value
n (% of total) n (%) n (%)
Infant Characteristics
Age (Weeks)
Median (IQR) 6 (6-6) 6 (6-6) 6 (6-6) 0.442
Mean (SD) 6 (0.6) 6 (0.6) 5.9 (0.7)
Sex
Male 69 (53.9) 51 (73.9) 18 (26.0) 0.447
Female 59 (46.1) 40 (67.7) 19 (32.2)
Feeding
Exclusive Breastfeeding 122 (95.3) 86 (70.4) 36 (29.5) 0.672
Mixed Feeding 6 (4.7) 5 (83.3) 1 (16.6)
Birthweight (kg)
< 2.5 5 (3.9) 3 (60.0) 2 (40.0) 0.626
≥ 2.5 123 (96.1) 88 (71.5) 35 (28.4)
HIV Exposure
Not Exposed 89 (69.5) 62 (69.6) 27 (30.3) 0.590
Exposed 39 (30.5) 28 (73.6) 10 (26.3)
Nutritional Status
Stunted
No (HAZ ≥ -2) 107 (83.6) 78 (72.8) 29 (27.1) 0.310
Yes (HAZ < -2) 21 (16.4) 13 (61.9) 8 (38.0)
Wasted
No (WAZ ≥ -2) 119 (93.0) 86 (72.2) 33 (27.7) 0.281
Yes (WAZ < -2) 9 (7.0) 5 (55.5) 4 (44.4)
Mother’s Characteristics
Age (years)
<20 20 (15.6) 15 (75.0) 5 (25.0) 0.080
20-24 45 (35.2) 37 (82.2) 8 (17.7)
25-29 34 (26.6) 19 (55.8) 15 (44.1)
≥30 29 (22.7) 20 (68.9) 9 (31.0)
Highest Education Level
None 6 (4.7) 4 (66.7) 2 (33.3) 0.470*
Primary 40 (31.3) 25 (62.5) 15 (37.5)
Secondary 81 (63.3) 61 (75.3) 20 (24.6)
Tertiary 1 (0.8) 1 (100.0) 0 (0.0)
Water Source
Piped into house/yard 45 (35.2) 33 (75.0) 12 (25.0) 0.882
Protected well 5 (3.9) 4 (80.0) 1 (20.0)
Public borehole/tap and pipe 78 (60.9) 54 (80.0) 24 (20.0)
Shared Toilet Facility
No 24 (18.8) 17 (70.8) 7 (29.1) 0.975
Yes 104 (81.3) 74 (71.1) 30 (28.8)
Type of Toilet Facility
Flushing toilet 26 (20.3) 17 (65.4) 9 (34.6) 0.476
Pit latrine 102 (79.7) 74 (72.6) 28 (27.5)
Abbreviations: IQR- Interquartile range; Std.Dev- standard deviation; Kg- Kilogram; HAZ (height-for-age Z-score); HIV (human immunodeficiency virus); MR (measles-rubella vaccine); RV-IgA (rotavirus specific immunoglobulin A); WAZ (weight-for-age Z-score); WLZ (weight-for-length Z-score). * Fisher’s exact test.
Table 2. Maternal and infant HBGA profiles and anti-rotavirus IgA titres 1- month post ROTARIX® dose 2.
Table 2. Maternal and infant HBGA profiles and anti-rotavirus IgA titres 1- month post ROTARIX® dose 2.
Characteristics Number of mother-infant pairs (% of total) GMTs (95% CI) ANOVA P-value Seroconversion (n = 37, 28.9%) Chi-Square P-value Crude Odds Ratio (95% CI) P-value
n (%)
Infant
Infant HBGA Phenotype
A 22 (17.2) 2.5 (0.9, 6.8) 0.874 7 (31.8) 0.929 ref
AB 3 (2.3) 1.6 (0, 270.6) 1 (33.3) 1.1 (0.1, 13.9) 0.958
O 103 (80.5) 1.9 (1.2, 3) 29 (28.2) 0.8 (0.3, 2.3) 0.731
Infant Lewis Phenotype
Le- (Le a-b-) 46 (35.9) 2.6 (1.3, 5.2) 0.332 14 (30.4) 0.775 ref
Le+ (Le a+b-,Le a-b+, or Le a+b+) 82 (64.1) 1.7 (1.1, 2.8) 23 (28.2) 0.9 (0.4, 2) 0.775
Secretor Phenotype
Non-secretor (se) 24 (18.8) 1.3 (0.6, 2.8) 0.279 5 (20.8) 0.24 ref
Secretor Phenotype (Se) 104 (81.3) 2.2 (1.4, 3.5) 32 (30.8) 1.7 (0.6, 4.9) 0.337
Infant FUT2 Genotype*
Homozygous secretor (GG) 60 (46.9) 1.4 (0.8, 2.5) 0.093 15 (25.0) 0.289 ref
Heterozygous secretor (GA) 4 (3.1) 5.6 (0, 1426.5) 2 (50.0) 3 (0.4, 23.2) 0.292
Non-secretor (AA) 18 (14.1) 4.9 (1.5, 16.3) 7 (38.9) 1.9 (0.6, 5.8) 0.255
Missing 46 (35.9) 2 (1, 3.8) 13 (28.3) - -
Mother
Lewis Phenotype
Le- (Le a-b-) 45 (35.2) 1.6 (0.9, 2.8) 0.358 13 (28.9) 0.997 ref
Le+ (Le a+b-,Le a-b+, or Le a+b+) 83 (64.8) 2.3 (1.4, 3.9) 24 (28.9) 1.0 (0.4, 2.2) 0.997
Secretor Phenotype
Non-secretor (se) 106 (82.8) 2 (1.3, 3.1) 0.85 32 (30.2) 0.336 ref
Secretor Phenotype (Se) 22 (17.2) 1.8 (0.7, 5.2) 5 (22.7) 0.7 (0.2, 2.0) 0.484
* Individuals with the genotype GG or GA at position 428 of the FUT2 gene are called homozygous and heterozygous secretors (Se) respectively while genotype. The G428A mutation in the FUT2 gene gives rise to an early stop codon, giving a truncated non-functional protein. Homozygous carriers of a nonsense mutation (AA) in this gene are called non-secretors (se). Abbreviations: GMT- Geometric mean titres, GMR-Geometric mean ratio; GMFR rise: Le-Lewis; Se-secretor.
Table 3. Maternal and Infant HBGA profiles and anti-rotavirus IgA titres at 12-months.
Table 3. Maternal and Infant HBGA profiles and anti-rotavirus IgA titres at 12-months.
Characteristics V12 GMTs ANOVA, P-value GMT Ratio (95% CI) P-value
GMT (95% CI)
Infant
Infant ABO Phenotype
A 5.02 (4.14, 6.07) 0.002 ref
AB 5.28 (1.86, 15) 0.59 (0.10, 3.47) 0.560
O 3.7 (3.35, 4.08) 0.36 (0.09, 1.41) 0.140
Infant Lewis Phenotype
Le- (Le a-b-) 3.57 (3.03, 4.22) 0.015 ref
Le+ (Le a+b-, Le a-b+, or Le a+b+) 4.17 (3.75, 4.63) 0.83 (0.31, 2.23) 0.705
Secretor Phenotype
Non-secretor (se) 2.89 (2.26, 3.71) < 0.001 ref
Secretor Phenotype (Se) 4.14 (3.78, 4.54) 1.94 (0.59, 6.4) 0.276
Infant FUT2 Genotype
Secretor (GG)/(GA) 3.95 (3.45, 4.52) 0.063 ref
Non-secretor (AA) 3.24 (2.44, 4.31) 1.66 (0.96, 2.83) 0.543
Mother
Lewis Phenotype
Le- (Le a-b-) 4.02 (3.52, 4.58) 0.521 ref
Le+ (Le a+b-, Le a-b+, or Le a+b+) 3.95 (3.51, 4.44) 1.09 (0.41, 2.88) 0.863
Secretor Phenotype
Non-secretor (se) 4.08 (3.72, 4.48) 0.368 ref
Secretor Phenotype (Se) 3.45 (2.64, 4.51) 0.83 (0.25, 2.70) 0.751
Treatment Arm
Control (MR) 4.08 (3.56, 4.67) 0.260 ref
Intervention (ROTARIX®+MR) 3.88 (3.44, 4.37) 1.39 (0.55, 3.49) 0.479
Abbreviations: GMT- Geometric mean titres, Le-Lewis; Se-secretor; MR-Measles rubella.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.
Prerpints.org logo

Preprints.org is a free preprint server supported by MDPI in Basel, Switzerland.

facebook logotwitter logolinkedin logo
MDPI Initiatives
Important Links
Subscribe

Disclaimer

Terms of Use

Privacy Policy

© 2024 MDPI (Basel, Switzerland) unless otherwise stated